Upcoming patent expirations for top biologics like Keytruda and Eylea are paving the way for biosimilars to enter the market, promising major cost savings. Learn how these complex drugs work, who's developing them, and what it means for patients and providers.
Read more
Complex generic drugs like liposomal injections and inhalers face major scientific and regulatory hurdles before FDA approval. Unlike simple generics, they require advanced testing, costly development, and unclear guidelines - delaying affordable access for patients.
Read more